IRVINE, CA, AIVITA Biomedical has closed its Series B-2 financing round for up to $25 million.
AIVITA Biomedical, a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, has closed its Series B-2 financing round for up to $25 million. Financing was provided by several life sciences investment firms.
AIVITA Biomedical is engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient, and economical manufacturing systems that support its therapeutic pipeline and commercial line of skin care products.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about